PSA Doubling Time: What Your Number Actually Changes
Almost every man I meet with a rising PSA after treatment has already worked out his own PSA doubling time. The number carries real weight — but only in the setting it was built for, and almost never before treatment.
Your PSA doubling time is the number of months it would take your PSA to double at its current rate of rise. It is arithmetic, not a diagnosis, and that distinction decides how much weight the number deserves. After a prostatectomy or radiation, doubling time is one of the strongest predictors we have of whether a rising PSA stays a number on a page or becomes disease visible on a scan. Before any treatment has happened, during ordinary screening, it predicts almost nothing — and the American Urological Association says so in plain language. Most men land on a calculator, get a figure like 7.4 months, and have no way to tell which of those two situations they are in. This article settles that: what the number is built from, the three cutoffs that genuinely change what your urologist offers you, and the specific conditions that make a result worthless. For the wider picture on prostate testing and treatment, start with the Prostate Health Hub.
Key Takeaways
- PSA doubling time carries prognostic weight after treatment for prostate cancer. In screening, the AUA/SUO guideline states as a Strong Recommendation that PSA velocity must not be the sole reason for a biopsy, imaging, or a second biomarker test.
- Three cutoffs change management: 6 months or less favors adding hormone therapy to salvage radiation, 9 months or less defines high-risk biochemical recurrence in the 2026 AUA/SUO guideline, and 12 months or less places you in the EAU high-risk group.
- A doubling time built from results run at different laboratories or on different assays is not a real number. Use one lab, one assay, and at least three values spanning three months or more.
- Even in fast-rising disease, the timescale is years, not weeks. In the Johns Hopkins cohort the median time from a rising PSA to visible metastasis was 8 years.
What Your PSA Doubling Time Actually Measures
PSA released by prostate tissue enters the bloodstream at a rate roughly proportional to how much of that tissue exists. When cancer cells are dividing, their number grows exponentially rather than in a straight line — so the PSA they produce climbs exponentially too. Doubling time is simply the exponential curve translated into a single interval: at this rate, how long until the number is twice what it is now.
Mathematically the calculation fits a straight line through the natural logarithm of your PSA values plotted against time, then divides the natural log of 2 by the slope of that line. You do not need to do this by hand — our PSA doubling time calculator takes your values and dates and returns the interval in months, along with the thresholds it crosses.
What the calculator cannot do is check whether your inputs deserve to be there. Three conditions have to hold before the output means anything:
- Same laboratory, same assay. Different PSA assays are calibrated differently and can disagree by 20 percent or more on the identical sample. Two labs alternating across four results can manufacture a rise that does not exist.
- Enough spacing. The Freedland analysis that produced the risk bands still in use required at least two values drawn at least 3 months apart. Two results a fortnight apart produce a doubling time that is mostly measurement noise.
- Enough points. Two values give you a doubling time with no way to detect an outlier. Three or more let the line ignore a single aberrant result.
One more input trap: ultrasensitive PSA assays report to three decimal places, standard assays to two. Mixing a 0.03 from an ultrasensitive assay with a 0.05 from a standard one is comparing two different measurements, and the doubling time that falls out of it is fiction.
In My Practice
A man came to my clinic two years after a radical prostatectomy carrying a printed spreadsheet. He had six PSA values, a fitted curve, and a doubling time of 4.1 months that he had calculated himself, and he had not slept properly for a fortnight. Going through the source reports with him, three of the six had come from his insurer’s contracted lab on an ultrasensitive assay and three from the hospital on a standard one, in alternating order. Refitting the curve on the three hospital values alone gave a doubling time close to 19 months. Nothing about his cancer had changed between those two numbers.
Before interpreting any doubling time, I check that every value in it came from one laboratory running one assay — because the most alarming results I see are usually assay artefacts, not disease.
The Three Cutoffs That Change Treatment
Doubling time is not read as a continuous score in the clinic. It is read against specific thresholds, and each threshold exists because a guideline panel or a trial drew a line there. Knowing which line your number falls on tells you which conversation you are about to have.
The 9-month cutoff is the one that moved most recently. The 2026 amendment to the AUA/SUO Advanced Prostate Cancer Guideline splits men with a rising PSA and no visible metastases into low-risk and high-risk on this number alone, and the split has consequences: low-risk men are offered observation and should not be started on hormone therapy routinely, while high-risk men are offered androgen deprivation therapy combined with enzalutamide[3]. That recommendation rests on EMBARK, which enrolled 1,068 men whose doubling time was 9 months or less and followed them a median of 60.7 months. Five-year metastasis-free survival was 87.3 percent with enzalutamide plus leuprolide against 71.4 percent with leuprolide alone[7].
| Doubling time | Where the cutoff comes from | What it changes |
|---|---|---|
| 3 months or less | Freedland 2005, Johns Hopkins post-prostatectomy cohort | Worst prostate cancer-specific survival of any band; systemic treatment is discussed rather than observation |
| 6 months or less | AUA/ASTRO/SUO Salvage Therapy Guideline | Counts as a high-risk feature favoring the addition of androgen deprivation therapy to salvage radiation |
| 9 months or less | AUA/SUO Advanced Prostate Cancer Guideline, 2026 amendment; EMBARK entry criterion | Defines high-risk biochemical recurrence once local therapy is exhausted; ADT with enzalutamide is offered |
| 12 months or less | EAU biochemical recurrence risk groups | Places you in EAU high-risk BCR, alongside ISUP Grade Group 4 to 5 as the alternative trigger |
| 15 months or more | Freedland 2005 | Lowest-risk band; survival after recurrence is often prolonged and observation is frequently reasonable |
Two points men consistently miss when they read a table like this. First, the AUA and EAU cutoffs are not in conflict — they answer different questions. The EAU 12-month line sorts men for salvage decisions and imaging; the AUA 9-month line sorts men who have already exhausted local treatment. Second, doubling time never acts alone. In the EAU classification, ISUP Grade Group 4 to 5 disease places you in the high-risk group regardless of how slowly your PSA is rising[4].
What the Number Predicts, and Over What Time Frame
A rising PSA after treatment is not the same event as metastatic disease, and the gap between them is usually measured in years. Pound and colleagues followed 1,997 men after radical prostatectomy at Johns Hopkins; 315 developed a rising PSA, and of the 304 who were not started on immediate hormone therapy, 34 percent went on to visible metastases. The median time from the PSA rise to that point was 8 years, and once metastases appeared the median time to death was a further 5 years[6]. Doubling time, Gleason score and the interval from surgery to recurrence were the three variables that separated the men who progressed quickly from the men who did not.
Freedland’s later analysis turned those variables into survival estimates and produced the bands still in use — under 3 months, 3 to 8.9, 9 to 14.9, and 15 months or more. Median survival in the whole recurrent cohort had not been reached after 16 years of follow-up from the time of recurrence[5]. That statistic is the one I most often have to say out loud, because a man who has just been told his cancer is back is rarely thinking in decades.
This is also why a long doubling time is a reason not to treat, rather than a reason to treat cautiously. Androgen deprivation therapy drives testosterone to castrate levels deliberately, and the symptom picture it produces — fatigue, loss of muscle mass, hot flushes, loss of libido and erectile function, mood change, bone loss — is the same cluster described in low testosterone in men over 40, only induced on purpose and more severe. Starting that in a man whose PSA is doubling every 4 years buys very little and costs a great deal, which is exactly why the 2026 guideline tells us not to.
How often your PSA should be checked after prostatectomy, and what counts as a real riseRising PSA after prostate cancer treatment: what to track and when to escalate
Enter your email below to receive Dr. Khalid’s complete PSA & Prostate Cancer Decision Guide as a free, printable PDF.
When Your PSA Doubling Time Result Means Nothing
The single most common misuse I correct is a man who has never had prostate cancer calculating a doubling time from three screening PSAs and arriving in clinic convinced he needs a biopsy. That number does not do the job he thinks it does.
The AUA/SUO Early Detection of Prostate Cancer Guideline addresses this as a Strong Recommendation, Evidence Level Grade B: in men undergoing screening, PSA velocity should not be used as the sole indication for a secondary biomarker, imaging, or a biopsy[1]. The reasoning is that once a clinician already knows your age, your PSA, your rectal examination findings, your family history and your prior biopsy history, adding the rate of rise does not improve prediction of clinically significant cancer. The guideline goes further and notes a paradox — a very steep rise, above 3 ng/mL per year, tends to associate with inflammation on the eventual biopsy rather than with tumor. A prostate inflamed by prostatitis leaks PSA enthusiastically and can outpace many cancers.
Four other situations make the number uninterpretable:
- You are already on hormone therapy. ADT suppresses PSA production directly. The curve is now measuring your drug, not your disease.
- Your values sit below 0.1 ng/mL on an ultrasensitive assay. At that level, assay variability alone can swing a reading enough to generate a frightening doubling time from nothing.
- You are on active surveillance. Modern surveillance protocols are driven by MRI and repeat biopsy findings rather than PSA kinetics, for the same predictive reasons the screening guideline gives. Our page on active surveillance for prostate cancer sets out what actually triggers a change of plan.
- Something inflammatory happened recently. A urinary infection, prostatitis, a catheter, a cystoscopy or a biopsy can lift PSA for weeks. One inflated value inside a four-point series distorts the whole slope.
What to Do With Your PSA Doubling Time Number
Work through these in order before your next appointment. Each one is something you can do yourself or something specific to request.
- Pull the source reports and check the laboratory name and assay on each one. Discard any value that came from a different lab or a different assay type, then recalculate. Do this before you do anything else — it changes the answer more often than any other step.
- Establish which recurrence definition applies to you. After a prostatectomy, biochemical recurrence is a PSA of 0.2 ng/mL or above, confirmed on a second sample[2]. After radiation, the prostate is still in place and still makes PSA, so the threshold is the lowest value you reached plus 2 ng/mL. Men who confuse the two frequently panic at a level that is entirely expected. If you were treated with surgery and your PSA has never become detectable, our page on what undetectable PSA after prostatectomy means explains the reporting thresholds involved.
- Ask for your pathology Grade Group in writing. Both the AUA and EAU classifications weigh grade alongside doubling time, and neither number is interpretable without the other. Request it at the same visit rather than by phone afterwards.
- If your recalculated doubling time is 12 months or less, ask directly whether PSMA PET imaging is appropriate now. Ask at the appointment, not at the next annual review — the imaging decision is time-sensitive and salvage treatment works better earlier.
- If it is longer than 12 months, ask what interval your PSA should be repeated at and put the date in your calendar. A specific interval, in months, agreed out loud. Vague reassurance is how men end up back in clinic three years later with a number nobody tracked.
When a Rising PSA Needs an Urgent Call, Not a Calculator
Contact your urology team the same week — do not wait for a scheduled review — if a rising PSA is accompanied by any of these:
- New, persistent back, hip or rib pain, particularly pain that is worse at night or wakes you
- Numbness, weakness or new difficulty walking, or loss of bladder or bowel control — possible spinal cord compression, which is an emergency
- Unexplained weight loss or a marked drop in appetite
- A recalculated doubling time of 3 months or less on values you have confirmed came from a single laboratory and assay
- Visible blood in the urine, or a new inability to pass urine
Frequently Asked Questions About PSA Doubling Time
How many PSA results do I need before a PSA doubling time is reliable?
Two values at least 3 months apart is the published minimum, and that is what the Freedland risk bands were built on. In practice I want three or more values spanning at least 6 months, all from the same laboratory on the same assay. With only two points there is no way to tell an outlier from a trend, and a single inflated result will distort the entire slope.
My PSA doubling time is 7 months but my PSA is only 0.3 ng/mL. Does that need treatment?
It needs a conversation, not panic. After a prostatectomy, 0.3 ng/mL confirmed on a repeat sample meets the definition of biochemical recurrence, and a doubling time of 7 months places you in the high-risk group under both the AUA and EAU classifications. That combination usually prompts imaging and a salvage radiation discussion. It does not mean disease is visible anywhere, and at this PSA level it frequently is not.
What is the difference between PSA velocity and PSA doubling time?
Velocity is the absolute rise per year, in ng/mL per year. Doubling time is the proportional rise, in months. A jump from 0.1 to 0.2 and a jump from 4.0 to 8.0 have identical doubling times but wildly different velocities. After treatment, doubling time is the measure guidelines use. Our PSA velocity tracker calculates both from the same set of values.
Does a short PSA doubling time mean the cancer has already spread?
Not on its own. A short doubling time raises the probability that imaging will find something and shortens the time you have to act, which is why it drives the imaging decision. Detection still depends heavily on the absolute PSA level — in the UCLA and UCSF trial, PSMA PET localized recurrence in 38 percent of men below 0.5 ng/mL and 84 percent between 1.0 and 2.0. Our page on what a PSMA PET scan finds covers what follows a positive result.
Can PSA doubling time be calculated if I have never been treated for prostate cancer?
It can be calculated, but it should not change your management. The AUA/SUO Early Detection Guideline states as a Strong Recommendation that PSA rate of rise must not be the sole reason for a biopsy, imaging, or a second biomarker test in men being screened. A newly elevated PSA is repeated first, because a meaningful proportion return to normal on the second test.
References
- American Urological Association / Society of Urologic Oncology. Early Detection of Prostate Cancer: AUA/SUO Guideline. 2026 amendment. AUA
- American Urological Association / ASTRO / SUO. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline. AUA
- American Urological Association / Society of Urologic Oncology. Advanced Prostate Cancer: AUA/SUO Guideline. 2026 amendment. AUA
- European Association of Urology. EAU Guidelines on Prostate Cancer. 2026 edition. EAU
- Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433-439. PubMed
- Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591-1597. PubMed
- Freedland SJ, de Almeida Luz M, De Giorgi U, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer (EMBARK). N Engl J Med. 2023;389(16):1453-1465. PubMed
- Fendler WP, Calais J, Eiber M, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer. JAMA Oncol. 2019;5(6):856-863. PubMed
Dr. Muhammad Khalid
MBBS · FCPS (Urology) · MCPS (Gen. Surgery) · CHPE · CRSM · IMC #539472
Specialist urologist with 11+ years of clinical experience across tertiary teaching hospitals. Trained at Lady Reading Hospital and Khyber Teaching Hospital, Peshawar. Author of 5 peer-reviewed international publications in Cureus, WJSA, and AJBS. Procedural expertise: URS, PCNL, RIRS, TURP, TURBT, and major open urological surgery. Full profile →
This article is for educational purposes only and does not constitute medical advice. Always consult your physician or urologist for diagnosis and treatment decisions specific to your condition.
